Litiasis renal (Parte 1)

1 Scales CD Jr, Smith AC, Hanley JM; Project UDiA. Prevalence of kidney stones in the United States. Eur Urol 2012;62:160-5.
2 Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med 1989;111:1006-9.
3 Saigal CS, Joyce G, Timilsina AR; Urologic Diseases in America Project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int 2005;68:1808-14.
4 Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension and stone disease. Kidney Int 1999;55:2397-406.
5 Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005;293:455-62.
6 Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005;68:1230-5.
7 Rule AD, Bergstralh EJ, Melton LJ 3rd, et al. Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol 2009;4:804-11.
8 Madore F, Stampfer MJ, Rimm EB, et al. Nephrolithiasis and risk of hypertension. Am J Hypertens 1998;11:46-53.
9 Milose JC, Kaufman SR, Hollenbeck BK, et al. Prevalence of 24-hour urine collection in high risk stone formers. J Urol 2014;191:376-80.
10 10Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. J Urol 2014;192:316-24.
11 Turk C, Petrik A, Sarica K, et al. EAU guidelines on diagnosis and conservative management of urolithiasis. Eur Urol 2015; published online 26 Aug; doi:10.1016/j.eururo.2015.07.040. 12 Romero V, Akpinar H, Assimos DG. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol 2010;12:e86-96.
13 Stamatelou KK, Francis ME, Jones CA, et al. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23.
14 Yasui T, Iguchi M, Suzuki S, et al. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology 2008;71:209-13.
15 Soucie JM, Thun MJ, Coates RJ, et al. Demographic and geographic variability of kidney stones in the United States. Kidney Int 1994;46:893-9.
16 Pearle MS, Calhoun EA, Curhan GC, Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol 2005;173:848-57.
17 Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender prevalence of stone disease. J Urol 2007;177:979-82.
18 Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397-401.
19 Curhan GC, Willett WC, Speizer FE, et al. Intake of vitamins B6 and C and the risk of kidney stones in women. J Am Soc Nephrol 1999;10:840-5.
20 Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997;126:497-504.
21 Pak CY, Peterson R, Poindexter JR. Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis. J Urol 2001;165:378-81.
22 Parks JH, Goldfisher E, Asplin JR, et al. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 2002;167:1607-12.
23 Healy KA, Hubosky SG, Bagley DH. 24-hour urine collection in the metabolic evaluation of stone formers: is one study adequate? J Endourol 2013;27:374-8.
24 Nayan M, Elkoushy MA, Andonian S. Variations between  wo 24-hour urine collections in patients presenting to a tertiary stone clinic. Can UrolAssoc 2012;6:30-3.
25 Pak CY, Sakhaee K, Pearle MS. Detection of absorptive hypercalciuria type I without the oral calcium load test. J Urol 2011;185:915-9.
26 Hosking DH, Erickson SB, Van den Berg CJ, et al. The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 1983;130:1115-8.
27 Borghi L, Meschi T, Schianchi T, et al. Urine volume: stone risk factor and preventive measure. Nephron 1999;81(suppl 1):31-7.
28 Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996;155:839-43.
29 Ferraro PM, Taylor EN, Gambaro G, et al. Soda and other beverages and the risk of kidney stones. Clin J Am Soc Nephrol 2013;8:1389-95. 30 Odvina CV. Comparative value of orange juice versus lemonade in reducing stone-forming risk. Clin J Am Soc Nephrol 2006;1:1269-74.
31 Penniston KL, Steele TH, Nakada SY. Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation. Urology 2007;70:856-60.
32 Goldfarb DS, Asplin JR. Effect of grapefruit juice on urinary lithogenicity. J Urol 2001;166:263-7.
33 Shuster J, Jenkins A, Logan C, et al. Soft drink consumption and urinary stone recurrence -a randomized prevention trial. J Clin Epidemiol 1992;45:911-6.
34 Sumorok NT, Asplin JR, Eisner BH, et al. Effect of diet orange soda on urinary lithogenicity. Urol Res 2012;40:237-41.
35 Passman CM, Holmes RP, Knight J, et al. Effect of soda consumption on urinary stone risk parameters. J Endourol 2009;23:347-50.
36 Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest 2005;115:2598-608.
37 Pak CY, Britton F, Peterson R, et al. Ambulatory evaluation of nephrolithiasis. Classification, clinical presentation and diagnostic criteria. Am J Med 1980;69:19-30.
38 Sakhaee K, Maalouf NM, Sinnott B. Kidney stones 2012: pathogenesis, diagnosis, and management. J Clin Endocr Metab 2012;97:1847-60.
39 Matsumoto ED, Heller HJ, Adams-Huet B, et al. Effect of high and low calcium diets on stone forming risk during liberal oxalate intake. J Urol 2006;176:132-6.
40 Heller HJ. The role of calcium in the prevention of kidney stones. J Am Coll Nutr 1999;18(5 suppl):373S-8S.
41 Curhan GC, Willett WC, Speizer FE, et al. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001;59:2290-8.
42 Curhan GC, Willett WC, Knight EL, et al. Dietary factors and the risk of incident kidney stones in younger women—Nurses’ Health Study II. Arch Intern Med 2004;164:885-91.
43 Curhan GC, Willett WC, Rimm EB, et al. A prospective-study of dietary calcium and other nutrients and the risk of symptomatic kidney-stones. N Engl J Med 1993;328:833-8.
44 Taylor EN, Curhan GC. Dietary calcium from dairy and nondairy sources, and risk of symptomatic kidney stones. J Urol 2013;190:1255-9.
45 Hess B, Jost C, Zipperle L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998;13:2241-7.
46 Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354: 669-83.
47 Wallace RB, Wactawski-Wende J, O’Sullivan MJ, et al. Urinary tract stone occurrence in the Women’s Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. Am J Clin Nutr 2011;94:270-7.
48 Domrongkitchaiporn S, Sopassathit W, Stitchantrakul W, et al. Schedule of taking calcium supplement and the risk of nephrolithiasis. Kidney Int 2004;65:1835-41.
49 Holmes RP, Assimos DG. The impact of dietary oxalate on kidney stone formation. Urol Res 2004;32:311-6.
2007;177:1238-43.__ 1567-73
51 Mendonca CDG, Martini LA, Baxmann AC, et al. Effects of an oxalate load on urinary oxalate excretion in calcium stone formers. J Renal Nutr 2003;13:39-46.
52 Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001;59:270-6.
53 Knight J, Holmes RP, Assimos DG. Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urol Res 2007;35:111-7.
54 Krishnamurthy MS, Hruska KA, Chandhoke PS. The urinary response to an oral oxalate load in recurrent calcium stone formers. J Urol 2003;169:2030-3.
55 Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol2012;8:467-75.
56 Hatch M, Cornelius J, Allison M, et al. Oxalobacter sp reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int 2006;69:691-8.
57 Kaufman DW, Kelly JP, Curhan GC, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol 2008;19:1197-203.
58 Tang M, Larson-Meyer DE, Liebman M. Effect of cinnamon and turmeric on urinary oxalate excretion, plasma lipids, and plasma glucose in healthy subjects. Am J Clin Nutr 2008;87:1262-7.
59 Gettman M, Ogan K, Brinkley L, et al. Effect of cranberry juice consumption on urinary stone risk factors. J Urol 2005;174:590-4.
60 Terris MK, Issa MM, Tacker JR. Dietary supplementation with cranberry concentrate tablets may increase the risk of nephrolithiasis. Urology 2001;57:26-9.
61 Baxmann AC, De O G Mendonça C, Heilberg IP. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients. Kidney Int 2003;63:1066-71.
62 Ortiz-Alvarado O, Miyaoka R, Kriedberg C, et al. Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stoneforming patients. Urology 2011;77:1054-8.
63 Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol 2009;11:134-44.
64 Honow R, Laube N, Schneider A, et al. Influence of grapefruit-, orange- and apple-juice consumption on urinary variables and risk of crystallization. Br J Nutr 2003;90:295-300.
65 Wabner CL, Pak CY. Effect of orange juice consumption on urinary stone risk factors. J Urol 1993;149:1405-8.
66 Kang DE, Sur RL, Haleblian GE, et al. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol2007;177:1358-62; discussion 62; quiz 591.
67 Seltzer MA, Low RK, McDonald M, et al. Dietary manipulation with lemonade to treat hypocitraturic calcium nephrolithiasis. J Urol1996;156:907-9.
68 Aras B, Kalfazade N, Tugcu V, et al. Can lemon juice be an alternative to potassium citrate in the treatment of urinary calcium stones in patients with hypocitraturia? A prospective randomized study. Urol Res 2008;36:313-7.
69 Koff SG, Paquette EL, Cullen J, et al. Comparison between lemonade and potassium citrate and impact on urine pH and 24-hour urine parameters in patients with kidney stone formation. Urology 2007;69:1013-6.
70 Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009;20:2253-9.
71 Taylor EN, Stampfer MJ, Mount DB, et al. DASH-style diet and 24-hour urine composition. Clin J Am Soc Nephrol 2010;5:2315-22.
72 Nouvenne A, Meschi T, Prati B, et al. Effects of a low-salt diet on idiopathic hypercalciuria in calcium-oxalate stone formers: a 3-mo randomized controlled trial. Am J Clin Nutr 2010;91:565-70.
73 Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J  ed 2002;346:77-84.
74 Rodriguez LM, Santos F, Malaga S, et al. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron 1995;71:416-8.
75 Lindell A, Denneberg T, Edholm E, et al. The effect of sodium intake on cystinuria with and without tiopronin treatment. Nephron 1995;71:407-15.
76 Norman RW, Manette WA. Dietary restriction of sodium as a means of reducing urinary cystine. J Urol 1990;143:1193-5.
77 Peces R, Sanchez L, Gorostidi M, et al. Effects of variation in sodium intake on cystinuria. Nephron 1991;57:421-3.
78 Breslau NA, Brinkley L, Hill KD, et al. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988;66:140-6.
79 Kok DJ, Iestra JA, Doorenbos CJ, et al. The effects of dietary excesses in animal protein and in sodium on the composition and the crystallization kinetics of calcium oxalate monohydrate in urines of healthy men.  Clin Endocrinol Metab 1990;71:861-7.
80 Lemann J. Relationship between urinary calcium and net acid excretion as determined by dietary protein and potassium: a review. Nephron 1999;81:18-25.
81 Bushinsky DA, Parker WR, Alexander KM, et al. Metabolic, but not respiratory, acidosis increases bone PGE(2) levels and calcium release. Am J Physiol Renal 2001;281:F1058-66.
82 Sutton RAL, Wong NLM, Dirks JH. Effects of metabolic-acidosis and alkalosis on sodium and calcium-transport in the dog kidney. Kidney Int 1979;15:520-33.
83 Yeh BI, Sun TJ, Lee JZ, et al. Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH. J Biol Chem 2003;278:51044-52.
84 Moe OW, Huang CL. Hypercalciuria from acid load: renal mechanisms. J Nephrol 2006;19:S53-61.
85 Maalouf NM, Moe OW, Adams-Huet B, et al. Hypercalciuria associated with high dietary protein intake is not due to acid load. J Clin Endocrinol Metab 2011;96:3733-40.
86 Zerwekh JE, Holt K, Pak CY. Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int 1983;23:838-41.
87 Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996;144:25-33.
88 Dussol B, Iovanna C, Rotily M, et al. A randomized trial of low-animalprotein or high-fiber diets for secondary prevention of calcium nephrolithiasis. Nephron Clin Pract 2008;110:c185-94.
89 Türk C, Knoll T, Petrik A, et al, eds. Guidelines on urolithiasis. EAU guidelines, edition presented at the 29th EAU annual congress, Stockholm ISBN, 2011. http://uroweb.org/wp-content/uploads/22-Urolithiasis_LR_full.pdf.
90 Tracy CR, Best S, Bagrodia A, et al. Animal protein and the risk of kidney stones: a comparative metabolic study of animal protein sources. J Urol 2014;192:137-41.
91 Fink HA, Wilt TJ, Eidman KE, et al. Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians clinical guideline. Ann Intern Medic 2013;158:535-43.
92 Borghi L, Meschi T, Guerra A, et al. Randomized prospective study of a nonthiazide diuretic,  indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol 1993;22(suppl 6):S78-86.
93 Ettinger B, Citron JT, Livermore B, et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol1988;139:679-84.
94 Brocks P, Dahl C, Wolf H, et al. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet 1981;2:124-5.
95 Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. Acta Med Scand 1984;215:383-9.
96 Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol1986;18:265-9.
97 Ala-Opas M, Elomaa I, Porkka L, et al. Unprocessed bran and intermittent thiazide therapy in prevention of recurrent urinary calcium stones. Scand J Urol Nephrol 1987;21:311-4.
98 Ohkawa M, Tokunaga S, Nakashima T, et al. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol 1992;69:571-6.
99 Ahlstrand C, Sandvall K, Tiselius H. Prophylactic treatment of calcium stone formers with hydrochlorothiazide and magnesium. In: Tiselius HG, ed. Renal stones—aspects on their formation, removal and prevention. Proceedings of the Sixth European Symposium on Urolithiasis, Stockholm, Linköping University 1995:195-7.
100 Fernandez-Rodriguez A, Arrabal-Martin M, Garcia-Ruiz MJ, et al. [The role of thiazides in the prophylaxis of recurrent calcium lithiasis.] Actas Urologicas Espanolas 2006;30:305-9.
101 Zerwekh JE, Holt K, Pak CY. Natural urinary macromolecular inhibitors: attenuation of inhibitory activity by urate salts. Kidney Int 1983;23:838-41.
102 Nicar MJ, Peterson R, Pak CYC. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol
1984;131:430-3.
103 Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol2007;177:1238-43
104 Barcelo P, Wuhl O, Servitge E, et al. Randomized double-blind-study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-4.
105 Ettinger B, Pak CYC, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997;158:2069-73.
106 Barcelo P, Wuhl O, Servitge E, et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993;150:1761-4.
107 Hoyer-Kuhn H, Kohbrok S, Volland R, et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol 2014;9:468-77.
108 Coe FL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder. Ann Intern Med 1977;87:404-10.
109 Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium-oxalate calculi. N Engl J Med 1986;315:1386-9.
110 Smith MJ. Placebo versus allopurinol for renal calculi. J Urol 1977;117:690-2.
111 Goldfarb DS, MacDonald PA, Gunawardhana L, et al. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol 2013;8:1960-7.
112 Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int 1986;30:422-8.
113 Ng CS, Streem SB. Contemporary management of cystinuria. J Endourol 1999;13:647-51.
114 Ng CS, Streem SB. Medical and surgical therapy of the cystine stone patient. Curr Opin Urol 2001;11:353-8.
115 Jaeger P, Portmann L, Saunders A, et al. Anticystinuric effects of glutamine and of dietary-sodium restriction. N Engl J Med 1986;315:1120-3.
116 Lindell A, Denneberg T, Edholm E, et al. The effect of sodium-intake on cystinuria with and without tiopronin treatment. Nephron 1995;71:407-15.
117 Rodman JS, Blackburn P, Williams JJ, et al. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol 1984;22:273-8.
118 Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol 2008;28:181-91.
119 Mission Pharmacal. Thiola (Tiopronin) tablets. Package insert. www. missionpharmacal.com/Global_Content/Package_Inserts/Thiola.pdf. 120 DeBerardinis RJ, Coughlin CR 2nd, Kaplan P. Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. J Urol 2008;180:2620-3.
121 Pak CY, Fuller C, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 1986;136:1003-8.
122 Michelakakis H, Delis D, Anastasiadou V, et al. Ineffectiveness of captopril in reducing cystine excretion in cystinuric children. J Inherit Metab Dis 1993;16:1042-3.
123 American Urological Association (AUA). Medical management of kidney stones: AUA guideline. 2014. www.auanet.org/common/pdf/education/clinical-guidance/Medical-Management-of-Kidney-Stones.pdf.124 Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009;20:2253-9.
125 Noori N, Honarkar E, Goldfarb DS, et al. Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 2014;63:456-63.
126 Rimer JD, An Z, Zhu Z, et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science 2010;330:337-41.
127 Sahota A, Yang M, Shikhel S, et al. Tailored inhibition of cystine stone formation as a therapy for cystinuria. J Inherit Metab Dis 2012;35 (suppl 1):S27